BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021
​ In Vivo Data from Makassar Base Editing Program Demonstrate Long-term Engraftment and Editing Retention at 16 Weeks CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that updated data fro